Revisiting What Might Save Life of Cancer Patients Actually

Bahram Alamdary Badlou

Research and Development Department, Zeist, The Netherlands

Dr. Bahram Alamdary Badlou, Research and Development Department, Zeist, The Netherlands.

Keywords: Cancer; Immune Thrombocytopenia; Myelofibrosis


Cancer patients 5-years survival chance (5YSC) is still after a Century research and development (R&D)do not changed significantly, as infectious diseases did. How Medici might increase 5YSC is not elucidated yet.
Recently I introduced death triangle machinery (DTM), which might play pivotal role in accelerating 5YSC toward increased morbidity and mortality rate in the last years [1].
Immune thrombocytopenia (ITP) is a common bleeding disorder caused primarily by auto-antibodies against platelet GPIIbIIIa and/or the GPIb-receptor complex.

View Full Text | Download PDF

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Total Articles Published


Track Your Article


Cient Periodique is a ‘Gold’ open access publisher that aspires to offer absolute free, unrestricted access to the valuable research information

We welcome all the eminent authors to submit your valuable paper

Cient Periodique invites the participation of honourable Editors and Authors

CPQ Journals provide Certificates for publication

Cient Periodique also offers memberships for potential Authors

Best Articles will be appreciated with the provision of corresponding Certificate